Research programme: antisense oligonucleotides and monoclonal antibody therapeutics- Gene Signal

Drug Profile

Research programme: antisense oligonucleotides and monoclonal antibody therapeutics- Gene Signal

Alternative Names: GS-156 mAB; GS-156 Small peptide; GS-168; GS-326; GS-497C

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Gene Signal
  • Class Antisense oligonucleotides
  • Mechanism of Action Gene expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Lung cancer
  • Research Cancer
  • No development reported Wounds
  • Discontinued Pancreatic cancer; Renal cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Wounds in France (Parenteral)
  • 16 Sep 2015 Preclinical trials in Lung cancer in France (Parenteral) before September 2015
  • 16 Sep 2015 Early research in Cancer in France (Parenteral) before September 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top